Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 6CNS 6NET 5Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 8Neuroendocrine Tumors 4Pancreatic Neoplasms 2Stomach Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Diseases 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Digestive System Neuroendocrine Tumor G1 1Digestive System Neoplasms 1Digestive System Diseases 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 1guadecitabine 1copper dotatate CU-64 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Ipilimumab 1Fluorodeoxyglucose F18 1CTLA-4 Antigen 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × lutetium Lu 177 dotatate × Gastrointestinal × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡